Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...
European markets opened higher on Tuesday, in a shortened trading session for Christmas Eve. At the opening bell, the ...
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...
Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...
Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...
Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...
The treatment, called CagriSema, led patients to lose 20% of their weight at 68 weeks in a late-stage study when looking at ...
Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...